Noticias de ARWR_US
Noticias del mercado
Últimas noticias sobre ARWR_US — 172 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
PASADENA, Calif., August 30, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) reached a major European milestone on August 17 when it announced the availability of REDEMPLO for adults with Familial Chylomicronemia Syndrome (FCS) in Germany. Following European Commission authorization in June 2026, the drug is now listed in the Lauer-Taxe database for prescribing and reimbursement. Unlike existing options requiring genetic confirmation, REDEMPLO […]
Some Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders may be a little concerned to see that the Independent...
Página 5 de 9